Prescient Therapeutics Limited (ASX:PTX)

21.5¢

right-arrow Created with Sketch. -0.015 (-6.52%)
MCAP $139.4M
Last trade 16.10pm 03/12/2021 20mins delayed

Latest Announcements

30/11/2021PTXPrescient Therapeutics Limited
30/11/2021PTXPrescient Therapeutics Limited
19/11/2021PTXPrescient Therapeutics Limited
12/11/2021PTXPrescient Therapeutics Limited
12/11/2021PTXPrescient Therapeutics Limited
6,914
MCap
12/11/2021PTXPrescient Therapeutics Limited
05/11/2021PTXPrescient Therapeutics Limited
04/11/2021PTXPrescient Therapeutics Limited

Company Overview

Prescient Therapeutics Limited is a clinical-stage oncology company. The Company is focused on developing therapies for a range of cancers, using CAR-T and targeted therapy approaches. The Company has a broad pipeline of cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. Its Phase 1b clinical candidate PTX-100 is a drug that blocks the cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). PTX-200, a Phase 1b/2a clinical candidate is a PH domain inhibitor that inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Its OmniCAR, is an immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product is for the treatment of Acute Myeloid Leukemia (AML), Her2+ solid tumors, including breast, ovarian and gastric cancers and glioblastoma multiforme (GBM).

PTX in the news

Clinical-stage oncology company Prescient Therapeutics (PTX) eyes several milestones across its anti-cancer…
Prescient Therapeutics (PTX) will present new results this week for its OmniCAR…
Prescient Therapeutics (PTX) advanced its clinical programs during the June quarterThe oncology…
Prescient Therapeutics (PTX) progresses a trial of its cancer-blocking drug, PTX100, following…

Search Previous Announcements